A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

ClinicalTrials.gov ID: NCT05110976

Public ClinicalTrials.gov record NCT05110976. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled corticosteroids / Long-acting beta-agonists (Part B)

Study identification

NCT ID: NCT05110976
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 170 participants

Conditions and interventions

Conditions

Asthma

Interventions

AZD8630 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 16, 2021 (Actual)
Primary completion: Aug 2, 2023 (Actual)
Completion: Aug 2, 2023 (Actual)
Last update posted: Aug 30, 2023

2021 – 2023

United States locations

U.S. sites: 18
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
Research Site	Tempe	Arizona	85283	—
Research Site	Bakersfield	California	93301	—
Research Site	Glendale	California	91206	—
Research Site	San Jose	California	95117	—
Research Site	Homestead	Florida	33030	—
Research Site	Miami	Florida	33122	—
Research Site	Miami	Florida	33144	—
Research Site	Miami	Florida	33155	—
Research Site	Miami	Florida	33173	—
Research Site	Miami	Florida	33175	—
Research Site	Boise	Idaho	83706	—
Research Site	White Marsh	Maryland	21162	—
Research Site	North Dartmouth	Massachusetts	02747	—
Research Site	Ann Arbor	Michigan	48105	—
Research Site	Raleigh	North Carolina	27607	—
Research Site	Toledo	Ohio	43617	—
Research Site	Portland	Oregon	97202	—
Research Site	El Paso	Texas	79903	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05110976, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 30, 2023 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05110976 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →